Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $27.2250 (5.36%) ($24.8200 - $27.6200) on Wed. Sep. 2, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.89% (three month average) | RSI | 91 | Latest Price | $27.2250(5.36%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 2.7% a day on average for past five trading days. | Weekly Trend | TGTX advances 6.9% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(64%) ARKG(59%) IWO(57%) ARKK(56%) IBB(55%) | Factors Impacting TGTX price | TGTX will decline at least -1.945% in a week (0% probabilities). VIXM(-36%) VXX(-33%) UUP(-18%) IGOV(-4%) DRIV(-4%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.945% (StdDev 3.89%) | Hourly BBV | 2 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | 5 Day Moving Average | $25.32(7.52%) | 10 Day Moving Average | $24.53(10.99%) | 20 Day Moving Average | $22.81(19.36%) | To recent high | 0% | To recent low | 62.1% | Market Cap | $3.448b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |